Company news
Shandong Lukang Pharmaceutical Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(600789)"Shandong Lukang Pharmaceutical Co., Ltd."Report for Q3 2026
October 28, 2026
(600789)"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Routine Related Party Transactions for 2027
October 28, 2026
(600789)"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Resolutions of the 18th (Extraordinary) Meeting of the 11th Board of Directors
October 28, 2026
(600789)"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing
October 28, 2026
(600789)"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Change in Accounting Policies
October 28, 2026
(600789)"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Adjustment of Construction Content and Extension of Certain Raised Funds Investment Projects
October 28, 2026
(600789)"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Resignation of Director and Election of Employee Representative Director
October 16, 2026
(600789)"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Resolutions of the 17th (Extraordinary) Meeting of the 11th Board of Directors
September 29, 2026
(600789)"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate
September 29, 2026
(600789)"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Adjustment to Certain Senior Executives
September 29, 2026
Announcement on Change of the Signing Certified Public Accountant
September 29, 2026
Announcement on Obtaining Drug Registration Certificate and Approval Notice for Marketing Application of Chemical API
September 22, 2026
Announcement on Convening the 2026 Semi-annual Performance Briefing
September 8, 2026
Special Report on the Deposit, Management and Actual Use of Raised Funds
August 28, 2026
Announcement on the Controlled Subsidiary Obtaining the Supplementary Application Approval Notice for Crisaborole Ointment and Becoming the Marketing Authorization Holder of the Drug
August 19, 2026
Announcement on Obtaining Notice of Approval for Marketing of Chemical API for Lenvatinib Mesylate
August 12, 2026
Announcement on Obtaining Drug Registration Certificate
August 7, 2026
Announcement on Investment in Construction of Green Bio‑manufacturing Project by Wholly‑owned Subsidiary
August 5, 2026
Announcement on the Proposed Selection in the 12th Batch of National Centralized Drug Procurement
August 3, 2026
Announcement on Completion of Industrial and Commercial Change Registration by a Wholly-Owned Subsidiary
July 27, 2026
Announcement on Obtaining Drug Registration Certificate and Notice on Approval for Marketing of Chemical API
July 16, 2026
Announcement on Implementation of Dividend Distribution for 2025
July 6, 2026
Announcement on Change of Name and Business Scope of Wholly-owned Subsidiary
July 3, 2026
Announcement on Acquisition of Drug Registration Certificate by a Holding Subsidiary
July 2, 2026
Announcement on Circulation of Restricted Shares Issued to Specific Objects
June 23, 2026
Announcement on Obtaining Approval for Marketing of Chemical API Aprepitant
June 22, 2026
Announcement on Obtaining Drug Registration Certificate
June 17, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 29, 2026
Annual Report on Continuous Supervision for 2025 of Shandong Lukang Pharmaceutical Co., Ltd. by China International Capital Corporation Limited
April 30, 2026
Announcement on Resolutions of the 13th Meeting of the 11th Board of Directors
April 24, 2026
Announcement on Progress in Bid for the Equity of Shandong Luhang Hecheng Pharmaceutical Co., Ltd.
April 17, 2026
Announcement on Completion of Inclusion of the First Subject in Phase IIb Clinical Trial of CMS203 Tablets
March 30, 2026
Announcement on the Holding Subsidiary Obtaining the Supplementary Application Approval Notice for Sildenafil Citrate Tablets and Becoming the Marketing Authorization Holder of the Drug
March 25, 2026
Announcement on Acquisition of Drug Registration Certificate by a Holding Subsidiary
February 24, 2026
Announcement on Progress in Receiving Land Collection and Storage Compensation for the Southern Factory Area
February 13, 2026
Announcement on "Corporate Value and Return Enhancement" Action Plan
February 6, 2026
Earnings Preannouncement for 2025
January 27, 2026
Announcement on Using Partial Idle Raised Funds to Temporarily Supplement Current Capital
January 23, 2026
Announcement on the Results of Issuing Shares to Specific Objects and Changes in Capital Stock
December 30, 2025
Announcement on the Company and Its Wholly-Owned Subsidiary Signing the Fundraising Special Account Custody and Supervision Agreement
December 23, 2025
Indicative Announcement on the Issuance of A-shares to Specific Objects in 2024
December 22, 2025
Announcement on Signing Trademark License Agreement with Related Parties and Related Party Transactions
December 11, 2025
Announcement on Obtaining Government Subsidies
December 8, 2025
Prospectus for Issuance of A-shares to Specific Objects in 2024 (Registration Draft)
December 2, 2025
Announcement on the Company and Its Holding Subsidiaries Being Selected as Successful Bidders in the 11th Round of National Centralized Drug Procurement
November 7, 2025
Report for Q3 2025
October 30, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
October 10, 2025
Announcement on Obtaining Registration Approval of Application for Issuance of Shares to Specific Objects by China Securities Regulatory Commission
September 29, 2025
Announcement on Resolutions of the 9th (Extraordinary) Meeting of the 11th Board of Supervisors
September 19, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
September 12, 2025